pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
476
stories
7d
GLP-1 compounder issues recall for copycat Zepbound
biopharma dive
7d
Roche affirms sales outlook amid doubts about its future
biopharma dive
7d
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
biospace
7d
Roche talks up Phase 3 success rate as it unveils pipeline cuts
endpoints
7d
Rebranded NodThera plans IPO to fund NLRP3 inhibitor’s push toward approval
fiercebiotech
8d
Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients
biospace
8d
Astellas links up with AI Proteins in $400M computational drug discovery deal
fiercebiotech
9d
STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more
stat
10d
Sanofi breaks ground on insulin plant after securing German government support
biospace
10d
Pathos inks BMS, Tempus collabs to apply agentic AI in Alzheimer's clinical development
fiercebiotech
10d
Veradermics’ minoxidil pill improves hair coverage in men in Phase 3
biospace
10d
Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery
fiercebiotech
10d
Investment firm TCGX picks migraine biotech TriGemX to take public via SPAC
fiercebiotech
10d
From strategy to scale: How Saudi Arabia is building a biotech ecosystem
biopharma dive
10d
Should amylin have been obesity therapeutics’ primary target from the start?
biospace
13d
Hospitals’ next lucrative bet — longevity clinics
stat
13d
CHMP endorses Eli Lilly’s GLP-1 pill and three other new drugs
endpoints
14d
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
biospace
14d
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
biospace
15d
‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
biospace
15d
STAT+: FDA adcomm members’ ties to industry under scrutiny
stat
15d
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
15d
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
biospace
15d
Why OMass’ $310M series C marks ‘fantastic milestone’ on journey to become ‘Britain’s Big Biotech’
fiercebiotech
16d
Roche extends China deal streak with $1B pact for RNAi obesity drug
biopharma dive
16d
STAT+: Doctors are giving generously to doctors running for office
stat
16d
Saudi Arabia takes actionable steps to build its biotech sector after 46 agreements in Riyadh
fiercebiotech
16d
Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race
fiercebiotech
17d
Pharma’s $500B patent problem will come in waves — not as a cliff
biopharma dive
20d
GSK drinks in Chai Discovery’s AI models after wet-lab validation
fiercebiotech
← prev
page 2 of 16
next →
